PAC 14028

Drug Profile

PAC 14028

Alternative Names: PAC 14028

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorepacific
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Pruritus; Rosacea; Seborrhoeic dermatitis
  • Discontinued Skin disorders

Most Recent Events

  • 10 Jan 2017 Chemical structure information added
  • 10 Jan 2017 Discontinued - Phase-I for Skin disorders (In volunteers) in South Korea (PO)
  • 10 Nov 2016 Phase-III clinical trials in Atopic dermatitis (In adults, In adolescents) in South Korea (Topical) (NCT02965118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top